Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Douglas G Adler, Annika Bergquist, Roger W Chapman, Lissy de Ridder, Mark Deneau, Johan Fevery, Corinne Gower-Rousseau, Lipika Goyal, Batul Kaj-Carbaidwala, Jochen K Lennerz, Kate D Lynch, Uzma Shah, Catherine A M Stedman, David C Wilson, Harland S Winter

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: United States : Journal of pediatric gastroenterology and nutrition , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 736578

Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma. When a child is diagnosed with both PSC and inflammatory bowel disease (IBD), evidence-based information on counseling families and risk management of developing cholangiocarcinoma is limited. In this case series (PubMed/collaborators), we included patients with PSC-IBD who developed cholangiocarcinoma and contacted authors to determine an event curve specifying the time between the second diagnosis (IBD or PSC) and a diagnosis of cholangiocarcinoma. Review of n = 175 studies resulted in a cohort of n = 21 patients with pediatric-onset PSC-IBD-cholangiocarcinoma. The median time to development of cholangiocarcinoma was 6.95 years from the second diagnosis. Despite the small number, 38% of cholangiocarcinoma developed within the first 2 years, and 47% of patients developed cholangiocarcinoma in the transition period to adult care (age 14-25). Our findings highlight the importance of screening that extends over the so-called transition period from pediatric to adult care.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH